Dr. Howard S. Weintraub

• 
  www.sec.gov/Archives/edgar/data/771252/0001362310-07-00 - [Cached Version]
  Published on: 3/22/2007    Last Visited: 4/7/2007  

  Howard S. Weintraub, Ph.D. Director
  ...
  McGrath, Silverman, Block, Edelstein, Weintraub and Zarriello, the current directors, be nominated for re-election.
  ...
  Howard S. Weintraub, Ph.D., 63, has been a Director since March 2002.Dr. Weintraub has been a Principal of Landfall Ther.Consulting Group, a solo research consulting service, since July 2003.Dr. Weintraub retired from C. R. Bard, Inc., a medical device company, in 2003, where he was Vice President, R&D, Corporate Staff.From 1988 to 1998, he held a series of senior research and technology management positions at Bristol-Myers Squibb.Dr. Weintraub was previously associated with Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He also has authored or co-authored over 50 scientific publications and abstracts.Dr. Weintraub previously served as Chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly APhA), and was the Chairman of the Drug Metabolism sub-section of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.He is a member of the Board of Directors of the privately-held biotechnology firm, Bioenergy, Inc., where he also chairs the company's Scientific Advisory Board.He is a member of the Scientific Advisory Board of VeriChip Corporation and of the Ascent Technologies Group, Polymerix Corporation, a specialty development-stage pharmaceutical company, and the Strategic Advisory Board of Aderans Corp.
  ...
  Block, Edelstein, Weintraub and Zarriello.
  ...
  Zarriello, Weintraub and Block.
  ...
  Weintraub, Zarriello, Block and Edelstein.
  ...
  Weintraub, Zarriello, Block and Edelstein.
  ...
  Weintraub, Zarriello, Block and Edelstein served as members of the Compensation Committee.

• 
  www.rfidnews.org/news/2007/05/24/glucosesensing-microch - [Cached Version]
  Published on: 5/23/2007    Last Visited: 2/29/2008  

  Former C.R. bard executive Dr. Howard S. Weintraub to lead the development
  
  SO. ST. PAUL, MN (May 23, 2007) -- Digital Angel Corporation (Amex: DOC), an advanced technology company in the field of rapid and accurate identification, location tracking and condition monitoring of high-value assets, and VeriChip Corporation (NASDAQ: CHIP), a provider of RFID systems for healthcare and patient-related needs, announced today they have established a joint committee to design and develop a working, implantable glucose microchip to determine glucose levels in the bodies of animals and humans, negating the need for diabetics to draw blood in order to monitor their individual blood glucose levels.The committee will oversee future clinical trials in animals and humans, and is also responsible for selecting technology and marketing partners.The goal for the chip is to function inside the body for a period of at least six months.
  
  The committee is led by Dr. Howard S. Weintraub, and also includes Zeke Mejia, Digital Angel's Animal Applications Chief Technology Officer, Yuri Smirnov, Digital Angel's Animal Applications Senior Radio Frequency Engineer, Jonathan Musher, M.D., VeriChip's Chief Medical Officer, Kevin N. McGrath, Digital Angel's President and Chief Executive Officer, and Scott R. Silverman, VeriChip's Chairman and Chief Executive Officer.
  ...
  Dr. Weintraub said, "Following our patent award in October 2006, we are positioned to begin development of a glucose microchip, which has the potential to revolutionize the way people with diabetes live and the medical care they receive.There are estimated to be hundreds of millions of people around the world living with diabetes, many of whom are not compliant with their care regimens due in large part to the discomfort and inconvenience of pricking their fingers numerous times per day.This chip could provide a painless way to quickly and accurately scan blood glucose levels to an external reader."
  
  Dr. Weintraub has been a Director of Digital Angel since March 2002.Dr. Weintraub retired from C. R.
  
  Bard, Inc., a medical device company, in 2003, where he was Vice President, R&D, Corporate Staff..From 1988 to 1998, he held a series of senior research and technology management positions at Bristol-Myers Squibb.Dr. Weintraub was previously associated with Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He also has authored or co-authored over 50 scientific publications and abstracts.Dr. Weintraub previously served as chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly APhA), and was the chairman of the Drug Metabolism sub-section of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.

• 
  www.sec.gov/Archives/edgar/data/1249569/0001200876-08-0 - [Cached Version]
  Published on: 1/2/2008    Last Visited: 1/3/2008  

  0001249569 WEINTRAUB HOWARD S C/O DIGITAL ANGEL CORPORATION 490 VILLAUME AVENUE SOUTH ST. PAUL MN 55075 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/771252/0001104659-06-02 - [Cached Version]
  Published on: 3/29/2006    Last Visited: 3/30/2006  

  Howard S. Weintraub, Ph.D.
  
  Director
  ...
  Howard S. Weintraub, Ph.D. has been a Director of the Company since March 2002.Dr. Weintraub retired from C. R. Bard, Inc., a medical device company, in 2003, where he was Vice President, R&D, Corporate Staff.From 1988 to 1998, he held a series of senior research and technology management positions at Bristol-Myers Squibb.Dr. Weintraub was previously associated with Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He also has authored or co-authored over 50 scientific publications and abstracts.Dr. Weintraub previously served as chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly APhA), and was the chairman of the Drug Metabolism sub-section of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.He is a member of the Board of Directors of the privately-held biotechnology firm, Bioenergy, Inc., and a member of the Scientific Advisory Board of Polymerix Corporation, a specialty development-stage pharmaceutical company.He was also a Board Advisor to the Swiss Biotechnology firm, Modex Therapeutics, prior to its merger with IsoTis, NV, in 2002.
  ...
  Block, Edelstein, Weintraub and Zarriello are "independent," as that term is defined in Section 121(A) of the AMEX Rules, except that Mr. Zarriello will not be considered independent with respect with transactions between the Company and ADSX.

• 
  www.sec.gov/Archives/edgar/data/771252/0001047469-04-01 - [Cached Version]
  Published on: 4/9/2004    Last Visited: 7/27/2004  

  Howard S. Weintraub, Ph.D. Director
  ...
  Howard S. Weintraub, Ph.D. has been a Director of the Company since March 2002.Dr. Weintraub retired from C. R. Bard, Inc., a medical device company, in 2003, where he was Vice President, R&D, Corporate Staff.From 1988 to 1998, he held a series of senior research and technology management positions at Bristol-Myers Squibb.Dr. Weintraub was previously associated with Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He also has authored or co-authored over 50 scientific publications and abstracts.Dr. Weintraub previously served as chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly APhA), and was the chairman of the Drug Metabolism sub-section of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.He is a member of the Board of Directors of the privately-held biotechnology firm, Bioenergy, Inc., and a member of the Scientific Advisory Board of Polymerix Corporation, a specialty development-stage pharmaceutical company.He was also a Board Advisor to the Swiss Biotechnology firm, Modex Therapeutics, prior to its merger with IsoTis, NV, in 2002.
  ...
  Block, Weintraub and Zarriello are "independent," as that term is defined in Section 121(A) of the AMEX Rules.

• 
  www.adsx.com/pressreleases/2007/2007-05-23-DA.html - [Cached Version]
  Published on: 5/23/2007    Last Visited: 12/10/2007  

  Former C.R. Bard Executive Dr. Howard S. Weintraub to Lead the Development
  ...
  The committee is led by Dr. Howard S. Weintraub, and also includes Zeke Mejia, Digital Angel's Animal Applications Chief Technology Officer, Yuri Smirnov, Digital Angel's Animal Applications Senior Radio Frequency Engineer, Jonathan Musher, M.D., VeriChip's Chief Medical Officer, Kevin N. McGrath, Digital Angel's President and Chief Executive Officer, and Scott R. Silverman, VeriChip's Chairman and Chief Executive Officer.
  ...
  Dr. Weintraub said, "Following our patent award in October 2006, we are positioned to begin development of a glucose microchip, which has the potential to revolutionize the way people with diabetes live and the medical care they receive.There are estimated to be hundreds of millions of people around the world living with diabetes, many of whom are not compliant with their care regimens due in large part to the discomfort and inconvenience of pricking their fingers numerous times per day.This chip could provide a painless way to quickly and accurately scan blood glucose levels to an external reader."
  
  Dr. Weintraub has been a Director of Digital Angel since March 2002.Dr. Weintraub retired from C. R. Bard, Inc., a medical device company, in 2003, where he was Vice President, R&D, Corporate Staff.From 1988 to 1998, he held a series of senior research and technology management positions at Bristol-Myers Squibb.Dr. Weintraub was previously associated with Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He also has authored or co-authored over 50 scientific publications and abstracts.Dr. Weintraub previously served as chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly APhA), and was the chairman of the Drug Metabolism sub-section of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.

• 
  www.digitalangelcorp.com/da/about_officers.aspx - [Cached Version]
  Published on: 11/23/2007    Last Visited: 11/23/2007  

  Howard S. Weintraub, Ph.D.

• 
  www.sec.gov/Archives/edgar/data/1249569/0001179110-06-0 - [Cached Version]
  Published on: 6/14/2006    Last Visited: 6/17/2006  

  0001249569 WEINTRAUB HOWARD S 490 VILLAUME AVENUE SOUTH ST. PAUL MN 55075 1 0 0 0

• 
  www.sec.gov/Archives/edgar/data/771252/0000912057-02-03 - [Cached Version]
  Published on: 9/26/2002    Last Visited: 9/28/2002  

  Howard S. Weintraub, Ph.D. Director
  ...
  Howard S. Weintraub, Ph.D. is Vice President, R&D, Corporate Staff for C.R. Bard, Inc., a medical device company (NYSE: BCR).He has been a Director of DIGITAL ANGEL CORP since March 27, 2002.From 1988 to 1998, he held senior research and technology management positions at Bristol-Meyers Squibb.Dr. Weintraub was previously associated with the Ortho Pharmaceutical Corporation, a Johnson and Johnson company, from 1973 until 1988, where he held senior research management positions.He has also authored or co-authored over 50 publications and abstracts.Dr. Weintraub previously served as chairman of the Industrial Pharmaceutical Technology Section of the AAPS (formerly AphA) and was the chairman of the Drug Metabolism subsection of the Research and Pharmaceutical Manufacturers' Association.Dr. Weintraub earned a Bachelor of Science Degree in Pharmacy from Columbia University and his Ph.D. in biopharmaceutics from the State University of New York at Buffalo.He serves on DIGITAL ANGEL CORP's Compensation and Audit Committees.He is also a Board Advisor to the Swiss biotechnology firm, Modex Therapeutics.
  
  Directors of DIGITAL ANGEL CORP are elected annually to serve until the next annual meeting of stockholders or until their earlier resignation, death or removal.There is no family relationship between any of the directors or executive officers of DIGITAL ANGEL CORP.

• 
  www.rfida.com/labels/innovation.htm - [Cached Version]
  Published on: 3/8/2008    Last Visited: 3/9/2008  

  Other initial members are: Howard Weintraub, Ph.D., a principal in Landfall Therapeutics Consulting Group, LLC and Sameer Mehta, MD, FACC, MBA, a highly respected cardiologist and healthcare activist. ...

Page:  1 2